Gemini Therapeutics (GMTX) vs. The Competition Financial Comparison

Gemini Therapeutics (NASDAQ:GMTXGet Rating) is one of 937 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare Gemini Therapeutics to similar companies based on the strength of its earnings, valuation, institutional ownership, dividends, analyst recommendations, risk and profitability.

Analyst Ratings

This is a summary of current ratings and recommmendations for Gemini Therapeutics and its peers, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gemini Therapeutics 0 3 2 0 2.40
Gemini Therapeutics Competitors 6050 20569 42952 855 2.55

Gemini Therapeutics currently has a consensus target price of $6.90, suggesting a potential upside of 333.96%. As a group, “Pharmaceutical preparations” companies have a potential upside of 92.04%. Given Gemini Therapeutics’ higher possible upside, equities analysts plainly believe Gemini Therapeutics is more favorable than its peers.

Earnings & Valuation

This table compares Gemini Therapeutics and its peers revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Gemini Therapeutics N/A -$71.87 million -0.88
Gemini Therapeutics Competitors $1.83 billion $238.78 million -1.91

Gemini Therapeutics’ peers have higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.


This table compares Gemini Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Gemini Therapeutics N/A -48.35% -43.70%
Gemini Therapeutics Competitors -4,343.49% -115.17% -11.41%

Insider and Institutional Ownership

59.0% of Gemini Therapeutics shares are held by institutional investors. Comparatively, 45.5% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by insiders. Comparatively, 14.4% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Gemini Therapeutics has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500. Comparatively, Gemini Therapeutics’ peers have a beta of 0.98, indicating that their average stock price is 2% less volatile than the S&P 500.


Gemini Therapeutics peers beat Gemini Therapeutics on 7 of the 13 factors compared.

About Gemini Therapeutics (Get Rating)

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with's FREE daily email newsletter.